IMRX
USDImmuneering Corporation Class A Common Stock
即時價格
價格圖表
關鍵指標
市場指標
開盤
$1.470
最高
$1.490
最低
$1.430
交易量
0.01M
公司基本面
市值
52.5M
行業
生物科技
國家
United States
交易統計
平均交易量
0.20M
交易所
NGM
貨幣
USD
52週範圍
相關新聞
Chardan Capital Maintains Buy on Immuneering, Maintains $13 Price Target
Chardan Capital analyst Geulah Livshits maintains Immuneering with a Buy and maintains $13 price target.
Immuneering Corporation Announces Grant of Inducement Award
CAMBRIDGE, Mass., March 21, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (NASDAQ:IMRX), a clinical-stage oncology company seeking to develop and commercialize more effective and better tolerated therapies for
Needham Reiterates Buy on Immuneering, Maintains $12 Price Target
Needham analyst Ami Fadia reiterates Immuneering with a Buy and maintains $12 price target.
Immuneering Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates
- Reported positive data updates from its ongoing Phase 2a trial of lead program IMM-1-104, including encouraging responses in combination with chemotherapy in first-line pancreatic cancer - - Announced a clinical
Immuneering Names Dr. Igor Matushansky as Chief Medical Officer
Industry veteran brings extensive oncology drug development expertise and experience in clinical treatment of cancer patients Dr. Matushansky joins as Immuneering plans to present updated data from Phase 2a trial of
